Roland, Christina L. http://orcid.org/0000-0003-3400-0087
Nassif Haddad, Elise F. http://orcid.org/0000-0003-3794-6759
Keung, Emily Z. http://orcid.org/0000-0002-8783-8484
Wang, Wei-Lien http://orcid.org/0000-0001-8809-4424
Lazar, Alexander J. http://orcid.org/0000-0002-6395-4499
Lin, Heather
Chelvanambi, Manoj http://orcid.org/0000-0003-2130-3118
Parra, Edwin R. http://orcid.org/0000-0001-9068-1636
Wani, Khalida
Guadagnolo, B. Ashleigh
Bishop, Andrew J.
Burton, Elizabeth M. http://orcid.org/0000-0002-3424-4922
Hunt, Kelly K. http://orcid.org/0000-0001-9156-8723
Torres, Keila E.
Feig, Barry W.
Scally, Christopher P.
Lewis, Valerae O. http://orcid.org/0000-0002-3170-636X
Bird, Justin E.
Ratan, Ravin
Araujo, Dejka
Zarzour, M. Alexandra
Patel, Shreyaskumar
Benjamin, Robert
Conley, Anthony P.
Livingston, J. Andrew http://orcid.org/0000-0002-1337-3282
Ravi, Vinod
Tawbi, Hussein A. http://orcid.org/0000-0003-1942-851X
Lin, Patrick P. http://orcid.org/0000-0002-1460-4994
Moon, Bryan S.
Satcher, Robert L.
Mujtaba, Bilal
Witt, Russell G.
Traweek, Raymond S.
Cope, Brandon
Lazcano, Rossana
Wu, Chia-Chin http://orcid.org/0000-0002-5208-6016
Zhou, Xiao
Mohammad, Mohammad M.
Chu, Randy A.
Zhang, Jianhua http://orcid.org/0000-0001-5412-9860
Damania, Ashish
Sahasrabhojane, Pranoti
Tate, Taylor
Callahan, Kate
Nguyen, Sa
Ingram, Davis
Morey, Rohini
Crosby, Shadarra
Mathew, Grace
Duncan, Sheila
Lima, Cibelle F.
Blay, Jean-Yves http://orcid.org/0000-0001-7190-120X
Fridman, Wolf Herman http://orcid.org/0000-0002-1332-0973
Shaw, Kenna
Wistuba, Ignacio
Futreal, Andrew http://orcid.org/0000-0001-8663-2671
Ajami, Nadim
Wargo, Jennifer A.
Somaiah, Neeta http://orcid.org/0000-0002-0146-7732
Funding for this research was provided by:
American College of Surgeons
Article History
Received: 13 June 2023
Accepted: 10 January 2024
First Online: 13 February 2024
Competing interests
: This study was supported by Bristol-Myers Squibb. A.J.L. has served on advisory boards and/or consulted for AbbVie, Adaptimmune, ArcherDX, AstraZeneca, Bayer, BMS, Deciphera Pharmaceuticals, Foghorn Therapeutics, Gothams, GSK, Guardant, Invitae, Illumina, Iterion Therapeutics, Merck, Novartis, Nucleai, Paige.AI, Pfizer, Roche/Genentech and Thermo Fisher. K.K.H. is on the medical advisory board for Armada Health and AstraZeneca and reports research funding to The MD Anderson Cancer Center from Cairn Surgical, Eli Lilly & Co. and Lumicell. D.A. receives research funding from Adaptimmune, GSK and Immatics. H.T. received grant or research support from BMS, Novartis, Merck, Genentech, GlaxoSmithKline, EMD Sereno, Eisai, Dragonfly Therapeutics, RAPT Therapeutics; and is a consultant for BMS, Genentech, Novartis, Merck, Boxer Capital, Karyopharm, Iovance, Eisai, Jazz Pharmaceuticals and Medicenna. R.G.W. is supported by the NIH T32 CA 009599 and The MD Anderson Cancer Center support grant P30 . J.Y.B. has received research support and honoraria from Roche, GlaxoSmithKline, BMS and MSD. W.H.F. is a consultant for Novartis, Adaptimmune, Anaveon, Catalym, OSE Immunotherapeutic, Oxford Biotherapeutics, Genenta and Parthenon. K.S. is a consultant for Guidepoint, GLG, BlueprintBiomedicines and Coleman and is on the editorial committee for a CSHP publication. I.W. has provided consulting or advisory roles for AstraZeneca/MedImmune, Bayer, Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Guardant Health, HTG Molecular Diagnostics, Merck, MSD Oncology, OncoCyte, Jansen, Novartis, Flame and Pfizer; has received grants and personal fees from Genentech/Roche, Bristol-Myers Squibb, AstraZeneca/MedImmune, HTG Molecular, Merck and Guardant Health; has received personal fees from GlaxoSmithKline and Oncocyte, Daiichi Sankyo, Roche, AstraZeneca, Pfizer and Bayer; and has received research funding to his institution from 4D Molecular Therapeutics, Adaptimmune, Adaptive Biotechnologies, Akoya Biosciences, Amgen, Bayer, EMD Serono, Genentech, Guardant Health, HTG Molecular Diagnostics, Iovance Biotherapeutics, Johnson & Johnson, Karus Therapeutics, MedImmune, Merck, Novartis, OncoPlex Diagnostics, Pfizer, Takeda and Novartis. J.A.W. reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol-Myers Squibb; is on the advisory board as a consultant for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Micronoma and Biothera Pharmaceuticals; and has stock options for Micronoma. N.S. is on the advisory board as a consultant for Deciphera, AADI Biosciences, Epizyme and Boehringer Ingelheim; receives research funding from Decipehra, Daiichi Sankyo, Karyopharm, AstraZeneca, Cogent Biosciences, Ascentage and GSK; and has an immediate family member with stock options from Pfizer and JNJ.